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ABSTRACT Sequence-specific binding to genomic-size DNA sequences by artificial agents is of major interest for the
development of gene-targeting strategies, gene-diagnostic applications, and biotechnical tools. The binding of one such
agent, peptide nucleic acid (PNA), to a randomized human genome has been modeled with statistical mass action
calculations. With the length of the PNA probe, the average per-base binding constant k0, and the binding affinity loss of a
mismatched base pair as main parameters, the specificity was gauged as a “therapeutic ratio” G  maximum safe
[PNA]tot/minimal efficient [PNA]tot. This general, though simple, model suggests that, above a certain threshold length of the
PNA, the microscopic binding constant k0 is the primary determinant for optimal discrimination, and that only a narrow range
of rather low k0 values gives a high therapeutic ratio G. For diagnostic purposes, the value of k0 could readily be modulated
by changing the temperature, due to the substantial H° associated with the binding equilibrium. Applied to gene therapy,
our results stress the need for appropriate control of the binding constant and added amount of the gene-targeting agent, to
meet the varying conditions (ionic strength, presence of competing DNA-binding molecules) found in the cell.
INTRODUCTION
There are numerous kinds of molecules capable of se-
quence-specifically recognizing parts of the genetic code
carried in the DNA (Nielsen, 1991; Ren and Chaires, 1999).
Besides giving valuable insight about the mechanisms of
molecular recognition in general, and of nucleic acids in
particular, the development and study of various gene-
targeting strategies have many other important practical
applications. These range from “pure chemical” gene diag-
nostic applications (Carlsson et al., 1996; Rufer et al., 1998;
Wang et al., 1997; Weiler et al., 1997) to various forms of
gene therapy based on man-made gene-targeting molecules
(Cohen and Hogan, 1994; Crooke, 1995). Also gene-repair
strategies based on targeting as a primary step to anchor the
correct gene sequence have been proposed (Chan et al.,
1999). The most promising gene-targeting agents so far
have been those based on various modifications of the
nucleic acid molecules themselves. To obtain more favor-
able properties, e.g., regarding binding strength, sequence
specificity and stability in biological liquids, a wide variety
of modifications has been explored (Cook, 1998; Uhlmann
and Peyman, 1990). The range of modifications include,
e.g., exchange of single atoms in the nucleic acid backbone,
substituents on the nucleobases, and other alternatives that
involve completely newly designed backbones.
Aimed to bind to DNA, and no matter how these mole-
cules look, an important question to be answered is whether
the efficiency and safety is high enough. To develop suc-
cessful gene drugs, i.e., with an optimized sequence speci-
ficity in the biological system, one needs to explore some
basic binding thermodynamics. It will turn out that it is not
only a matter of obtaining as high binding affinity for the target
sequence as possible, but in addition, and more importantly, to
minimize the drug binding to nontarget DNA, i.e., mismatched
target sequences. Moreover, the purpose of this is not only to
avoid blocking unwanted genes, but also to keep the drug
amount low in the cell to simultaneously avoid non-DNA
related toxicity and meet economical requirements.
Trying to optimize the concentration of drug delivered to
a cell is therefore a delicate act of balance between repress-
ing the gene (target) of interest while leaving normally
working genes unaffected. Here we want, in a simplified
manner, to discuss some aspects of this optimization process
regarding the molecular recognition.
Peptide nucleic acids (PNA) are DNA mimics with in-
teresting potential for gene-therapeutic, gene-diagnostic,
and molecular biology applications (Nielsen, 1999; Nielsen
and Egholm, 1999). Compared to other DNA analogs, PNA
has several advantageous binding properties, mainly arising
from the fact that the negatively charged backbone of DNA
is replaced by a neutral pseudopeptide in PNA. The back-
bone in PNA is composed of N-(2-aminoethyl)glycine units,
onto which the natural recognizing elements of DNA (the
nucleobases) are attached (Fig. 1). Designed to be structur-
ally homomorphous to DNA, a mixed-sequence PNA strand
is capable of hybridizing with complementary single-
stranded DNA, RNA, or another PNA strand to form highly
stable duplexes with high sequence selectivity (Egholm et
al., 1993; Kilså Jensen et al., 1997; Nielsen et al., 1991;
Tomac et al., 1996). At moderate salt, the thermal stabilities
increase in the series DNA–DNA  PNA–DNA  PNA–
RNA  PNA–PNA, mainly due to the lack of interstrand
electrostatic repulsion in PNA-containing duplexes
(Egholm et al., 1993; Tomac et al., 1996).
The hybridization affinity of PNA to DNA has been
modeled from a statistical viewpoint using thermodynamic
data previously determined for mixed purine–pyrimidine
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sequence PNA–DNA duplexes (Ratilainen et al., 2000).
Here, we introduce some basic models for estimating the
binding constants of PNA–DNA target sequences in com-
petition with mismatched targets, to a randomized human
genome. We show, using a set of simulations, that the
models need not to be very complex, but a rather simple
approach is sufficient for finding the appropriate drug con-
centration range to use in a therapeutic or biotechnical
application.
METHODS
Statistical modeling
Let the genome (DNA), of a certain length L, have a uniform distribution
of the four bases (A, C, G, and T) in a random sequence, with the exception
of one target sequence, T, to which a probe can bind with a binding
constant of K0 (M1). In our example, the probe will be a PNA oligomer
of length n bases, in a sequence complementary to T. On average, each
base will contribute a factor k0 (M1bp1) to the binding constant. The
equilibrium between PT (PNA bound to the target), P (free PNA), and T
(free, unblocked target sequences), can then be described by
PTL|;
K0
PT; K0  k0n 
PT
PT . (1)
Binding model 1: Two-state model (match or not)
In the most simple model of PNA binding to a sequence with m mis-
matches, we assume that the binding constant can be factorized into
sequence- and position-independent binding constants (per base): k0 for the
(n  m) matched basepairs and kmis for m mismatched basepairs,
Km  k0
nmkmis
m  k0
n fm 
PDm
PDm
, (2)
where Dm denotes a nontarget DNA sequence with m mismatches and, for
convenience, f  kmis/k0 defines the “frustration factor,” i.e., the penalty of
having one mismatch in the sequence.
Assuming the overall binding density of PNA to be low enough that
overlap of binding sites could be neglected, the concentration of free
sequences with m mismatches, [Dm], is calculated from the mass balance
condition,
[Dm] Dmtot  PDm] , (3)
where [PDm] denotes the concentration of PNA bound to sequences with
exactly m mismatches, and [Dm]tot denotes the total concentration of such
sequences. The latter quantity is given by
[Dm]tot  P	Dm
LDNA]tot , (4)
where P(Dm) is the probability for a consecutive sequence of n bases on the
DNA to have exactly m mismatches relative to the PNA, L is the number
of possible n-base sequences, which, because L  n, is equal to the
number of bases per DNA molecule, and [DNA]tot is the total concentration
of DNA molecules. Assuming a random DNA sequence with GC  AT,
P(Dm) is given by the binomial coefficient,
P	Dm
  nm14
nm34
m
. (5)
Note that D0 denotes a copy of the target that statistically may appear with
a certain probability in a random sequence model genome; thus, although
P(T)L  1, because, by hypothesis, the target sequence is present in the
genome, P(D0)L  1, in general.
The concentration of total (added) PNA can now be readily calculated
by summation of terms corresponding to free PNA, PNA targeting the
correct sequence as well as being bound to the various mismatched se-
quences,
[P]tot  P PT  PDm
 P PT 
m0
n k0
n fmP][Dmtot
1 k0n fmP
. (6)
Binding model 2: Mismatches with different costs
One step to refine the model is to categorize the different mismatches into
different classes, depending on their impact on the total binding constant of
the duplex. Based on previous results for singly mismatched PNA–DNA
duplexes (Ratilainen et al., 2000), we have chosen to lump the mismatches
into either of two classes: Class 1 with the energetically less costly ones,
i.e. GT, GA, GG, and AA with a frustration factor f1  102, and Class
2 containing CT, CA, TT, and CC with a frustration factor f2  103.
The binding affinity (equilibrium constant) of the probe to a target se-
quence is then given by Eq. 7, with I being the number of mismatches of
Class 1 and J the number of mismatches of Class 2,
KIJ  k0
n f 1
I f 2
J
. (7)
The calculation of the concentrations [DIJ] is done analogously with
Model 1, i.e., at the assumption that there be no effect of interactions with
the neighboring bases in the sequence. Thus, the PNA sequence can be split
into four parts, each containing only one type of base, and the probability
of having i mismatches of Class 1 and j mismatches of Class 2 in, for
example, the C (cytosine) part can be computed by
P	Cij
 14
wijCX14 
iCX24 
jwi w ij  , (8)
FIGURE 1 Chemical structures of DNA and PNA. The deoxyribose
phosphodiester backbone in DNA has been changed to N-(2-aminoethyl)
glycine in PNA.
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where w is the number of C bases in the PNA and CXx is the number of
basepairs in mismatch Class x, which contains at least one C base (with our
mismatch categories, CX1  0 and CX2  3). The three other parts, with
only A, G, and T bases, give analogous expressions.
The probability of a PNA sequence with totally I Class 1 mismatches
and J Class 2 mismatches, P(DIJ), is given by all combinations of the
product P(Aij)P(Cij)P(Gij)P(Tij) fulfilling the conditions ¥ i  (ia  ic 
ig  it)  I and ¥ j  (ja  jc  jg  jt)  J:
P	DIJ
 
¥iI, ¥jJ
P	Aiaja
P	Cicjc
P	Gigjg
P	Titjt
. (9)
The concentrations can be expressed analogously with Model 1, according
to
[P]tot  P PT  PDIJ
 P PT 
I,J0
IJn KIJPDIJtot
1 KIJP
, (10)
where
[DIJ]tot  P	DIJ
LDNA]tot (11)
Choice of parameters
The choice of parameters is quite critical for the outcome of the simula-
tions. As described above, estimations of the various binding constants are
taken from a set of experimental thermodynamic data for forming duplex
complexes with DNA (Ratilainen et al., 2000). We use a length-averaged
(6–20 bp) binding constant, k0  8.6 M1bp1 at 37°C, of matched
PNA–DNA duplexes (Ratilainen et al., 2000), with the different mis-
matches categorized in two classes as described above. Furthermore, as
default, we use a hypothetical randomized (with %GC  %AT) genome
with human DNA length (L  3  109 bases).
To obtain a value relevant for in vivo gene-targeting conditions, we
have used the local concentration of DNA in the nucleus of a eukaryotic
cell; on average 0.17 g/mL (Daban, 2000). This converts to 0.1 nM using
Mw  650 gmol1bp1 and L  3  109 bases.
Output from the calculations
With the free PNA concentration [P] as independent variable, concentra-
tions of blocked target, [PT] and the sum of the concentration of PNA
bound to mismatched sequences ¥[PDIJ] were calculated and plotted
versus total PNA concentration (Eq. 10). To make the results of the
simulation easier to visualize, the dominating terms in the summation, i.e.,
[PDIJ] for those mismatched sequences that were significantly (50%)
blocked, were plotted separately.
RESULTS AND DISCUSSION
Figure 2 shows a schematic graphical presentation of the
results in this work. Logarithmic concentration profiles of
free PNA, PNA bound to target, [PNAT], as well as the
sum of PNA bound to mismatched sequences, ¥[PDm]
(Model 1) and ¥[PDIJ] (Model 2), respectively, and a
stepwise curve representing the sum of PNA bound to
heavily blocked mismatched sequences (“critical mis-
matches” for which KIJ[P]  1) are all plotted as a function
of total PNA concentration, [PNA]tot. These are indicated,
together with the limit for binding to a mismatch to become
“dangerous” (left), and the “therapeutic range” (top). By
therapeutic range, we define the span from the point where
FIGURE 2 Graphical representation of the principle and some parameter
definitions used in the simulations for the two different binding models. (A)
Model 1 (one class of mismatches): The graphs show profiles of [PNAT]
(–  –), [PNA]free (– – –), ¥[PDm] (——), and ¥[PDm]crit (). The
therapeutic range is defined starting from the concentration at which 99%
targeting occurs until the integrated concentration of mismatched com-
plexes reach the specificity level (here chosen to be 100.5 times lower than
the concentration of targeted sequence). (B) Model 2 (two classes of
mismatches): The graphs show profiles of [PNAT] (–  –), [PNA]free
(– – –), ¥[PDIJ] (——), and ¥[PDIJ]crit (). The binding curves appear
somewhat more complex, and several details are changed. The singly (I 
J  1, indicated as 10 and 01) mismatched sequences now appear as two
branches and the doubly (I  J  2, i.e., 20, 11, and 02) as three (marked
with arrows in graph). Also, the curve for the free PNA concentration
appears more smoothed with different mismatches (Model 2) than with
only one type (Model 1). The therapeutic range, however, does not change
significantly.
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binding to target is considered complete (99%), to the point
where the collective (integrated) concentration of PNA-
bound mismatched sequences grows above a certain level
(left, typically a factor 100.5  3.2 lower than the covered
target concentration). The vertical lines in the graphs show
these two limits.
In the simplest case with only one type of mismatch
(Model 1), a rather clear picture of the binding is obtained
(panel A) even when considering the individual mismatches
(open circles). For two different types of mismatches (Mod-
el 2; panel B) the binding curves become more complex,
and several details are changed, especially regarding the
individual mismatches (open circles). For appropriate cases,
we will discuss the underlying values of the individual
mismatch concentrations. The concentration of these will
asymptotically approach a limiting concentration; in the
figures, each curve is truncated at the point where binding to
the subsequent mismatch starts to dominate.
Finding an optimal length of the PNA
(mixed sequences)
Using the previously determined (Ratilainen et al., 2000)
average binding constant per basepair PNA–DNA, k0 
(8.6  1) M1 (at 37°C), and the mismatch costs described
in the Methods section, we performed a series of calcula-
tions with mixed-sequence PNA–DNA duplexes of varying
lengths, from n  18 to n  20 (Fig. 3). Panel A (n  18)
represents a situation with conditions such that we do not
achieve sequence-specific binding. The vertical line point-
ing at the integrated mismatch curve, where it corresponds
to our criterion of 100.5 times lower concentration than the
blocked target, appears before the shorter line (marked
99%T) showing where the target is sufficiently blocked.
Moving on to longer PNA probes changes the order of these
limits and thus represents specific targeting, although the
therapeutic range is very narrow in both cases (panels B–C).
That further increasing n has little effect on the collective
concentration of mismatched sequences is also notable.
Different mismatches give different behavior
In Fig. 4, binding curves for four different 20-mer se-
quences are shown, each representing one pure sequence of
the four nucleobases, respectively. Because our categoriza-
tion of mismatches is such that all three C-containing mis-
matches belong to Class 1 (less costly, frustration factor
f1  102) and all the G-containing mismatches are of Class
2 (f2  103), whereas the homo-T- and homo-A-oligomers
represent the mixing of the two mismatch classes (33% and
67% Class 2, respectively), these four panels show the
meaning of different frustration factors.
We see that panel A with the C20 sequence and f1  102
giving a reasonably specific binding for a range from
1010.00 to 109.88 M, is quite similar to the other extreme,
panel D corresponding to a G20 with f2  103, even though
the therapeutic range is narrowed down to 109.95 to
109.88 M. Investigating the individual mismatch branches,
the same pattern emerges. However, looking at the mixed
cases, panels B and C, gives a completely different picture
FIGURE 3 Profiles of [PNAT] (–  –), [PNA]free (– – –), ¥[PDIJ]
(——), ¥[PDIJ]crit () simulated for three mixed PNA–DNA sequences
of varying length (N 18, 19, and 20). All three panels are simulated using
k0  8.6 M1bp1, at a DNA concentration of 0.1 nM. Sequences: (A)
A4C5G5T4, (B) A5C5G5T4, and (C) A5C5G5T5.
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of the individual mismatches. The two variants of singly
mismatched species appear in different shapes, and espe-
cially the first of the doubly mismatched sequences in panel
B (appearing around [PNA]tot  109.78 M) may thus have
to be considered with special caution. The overall mismatch
concentration, though, gives binding curves and therapeutic
ranges that fall linearly between the two extreme cases, A
and D. What needs to be remembered is that examples of
our simulations are based on rather arbitrary values of
frustrations factors corresponding to the two classes of
mismatches, and that the free-energy penalties are previ-
ously determined values taken from studies of single mis-
matches in 9- and 12-mer PNA–DNA duplexes formed with
single-stranded DNA at room temperature and low salt
(Ratilainen et al., 2000).
Choice of binding constant
Using mixed-sequence PNA–DNA duplexes, we previously
determined a length-averaged contribution of G/n 
(6.5  0.3) kJmol1bp1, corresponding to a binding
constant for one basepair (k0) of 14 M1 (at 25°C) (Ra-
tilainen et al., 2000). Moreover, resolving the thermody-
namics of PNA–DNA binding into enthalpic and entropic
terms yielded H/n  (30.0  2.5) kJmol1bp1 and
TS/n  (23.5  2.3) kJmol1bp1, respectively
(Ratilainen et al., 2000). Using these values, it is possible to
calculate the binding constant at any temperature from RT
ln k0(T) H  TS, if the enthalpy and entropy changes
upon hybridization are considered independent of tempera-
ture. Converting the observed value of the average binding
FIGURE 4 Profiles of [PNAT] (–  –), [PNA]free (– – –), ¥[PDIJ] (——), ¥[PDIJ]crit () simulated for 20-mer PNA–DNA sequences containing only
one type of base, at a DNA concentration of 0.1 nM, and using k0  8.6 M1bp1. (A) (C20) represent only Class 1 mismatches with a frustration factor
of 102, whereas panel (D) is Class 2 only (G20) with frustration factor 103. (B) (T20) and (C) (A20) illustrate mixing of the two Classes, i.e., 33% and
67% Class 2, respectively.
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constant for formation of one basepair (k0) yields 8.6 M1
at physiological 37°C. This value corresponds to conditions
with low ionic strength (10–100 mM NaCl), which implies
that the PNA–DNA value outperforms the binding constant
for DNA–DNA duplex formation by a factor of 3, and may
serve as a guideline for estimating duplex stability for
perfectly matched duplexes. At physiological salt condi-
tions (140 mM NaCl) the difference is expected to be even
lower, because the electrostatic repulsion between two DNA
backbones is reduced substantially in presence of salt
(Tomac et al., 1996). Consequently, in our simulations, we
have in addition used lower values of k0.
To keep the model calculation as simple as possible,
emphasizing the effect of correct versus incorrect basepair-
ing, we shall use one and the same k0 value for AT and GC
basepairs. For explicit cases of target calculations, of
course, different k0 values can be used and easily incorpo-
rated into the model.
In Fig. 5, we performed a series of simulations for the
mixed-sequence PNA 20-mer, letting the binding constant
correspond to different temperatures according to thermo-
dynamic properties of PNA–DNA duplexes determined pre-
viously (Ratilainen et al., 2000). In panel A, the human
physiological case (37°C) is shown, whereas panels B–D
demonstrate how delicately the balance is shifted between
50 and 60°C for this system. This might be very useful in
diagnostic applications where temperature often is used to
tune or select the detection of the correct sequence relative
to incorrect sequences (Carlsson et al., 1996). In a diagnos-
tic application, and from a detection-limit standpoint, one
may also have to consider which species gives rise to signal,
e.g., what is labeled. For example, if the free PNA contrib-
FIGURE 5 Profiles of [PNAT] (–  –), [PNA]free (– – –), ¥[PDIJ] (———), ¥[PDIJ]crit () simulated for four identical 20-mer PNA–DNA sequences
(A5C5G5T5) at different temperatures (37, 50, 55, and 60°C) resulting in different values of the binding constant k0. (A–D) represent k0  8.6, 5.4, 4.5, and
3.9 M1bp1, respectively. All four panels are simulated at a DNA concentration of 0.1 nM.
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utes to the detected signal, the case in panel C might imply
an upper limit to the temperature used, because the free
PNA concentration is of the same magnitude as the sum of
mismatches. Still, though, they are both much below the
target sequence concentration.
Figure 5 serves an additional purpose of showing the
critical (lowest) k0 value that still discriminates the target
sequence. For our mixed 20-mer, this corresponds to
k0,crit  4 M1bp1, and hence panels C (k0  4.6
M1bp1) and D (k0  3.9 M1bp1) represent situations
on either side of this limit. In panel D, the curve of the free
PNA concentration (dashed), crosses the curve of target
binding (dash-dotted) at a total PNA concentration around
109.7 M, i.e., before reaching the 99% targeting limit.
Thus, any further addition of PNA only increases correct
targeting marginally at the expense of significantly decreas-
ing drug economy.
The same series also shows how the therapeutic range
changes quite dramatically as k0 is varied in the vicinity of
the critical value. The point where the target is blocked
“enough” moves to even higher values as the binding
strength decreases (going from k0  5.4 M1bp1 to k0 
3.9 M1bp1), though, accompanied by a relatively larger
change of the lower specificity limit in the same direction
thus making the therapeutic range larger at the expense of
having to add unrealistic amounts of PNA.
At higher values of k0 (Fig. 5 A), we see, as in the other
simulations (Figs. 3 and 4), that the most striking feature is
the very narrow range of useful concentrations of drug
(PNA), thus setting a severe implication on the usefulness of
this class of sequence-specific DNA binders. Just adding
one extra base onto the probe can alter the concentration
profile(s) of the mismatched species (that needs to be ac-
counted for) considerably. Therefore, the optimal length
will be greatly dependent on such factors as temperature and
other physical conditions, e.g., salt. In the gene-targeting
application, the total concentration of DNA and temperature
is given, but we must keep in mind that the local structure
of DNA may vary widely, and the accessible (effective)
concentration may be significantly decreased. Another fac-
tor that may attenuate the binding scenario is the effective
PNA (drug) concentration. As for single-stranded DNA
(Holbrook et al., 1999), PNA sequences (particularly par-
tially self-complementary ones) may form back-folded or
partially double-stranded conformations, thereby lowering
the effective PNA concentration and thus competing with
the DNA targeting.
In more biotechnological or analytical applications, we
may ourselves choose optimal conditions with respect to
temperature and salt within certain practical limits. Also, in
diagnostic contexts, the analyses are seldom made directly
on the whole (human) genome, but on shorter stretches
containing the gene of interest.
General features of simulations
Even though the following discussion can be applied to
more sophisticated models, it is sufficient to consider the
simplest model to illustrate the main important factors that
govern the binding of PNA to DNA. Going back to the key
equation when calculating the total concentration of bound
PNA for the simplest case of binding, i.e., with only one
type of mismatches present (Model 1):
[PDm] L[DNA]tot nm14
nm34
m k0
n f mP
1 k0n f mP
 LDNA]totP	Dm
R. (12)
In the summation, the first part P(Dm) 
(mn )(1⁄4)nm(3⁄4)m, the probability of occurrence for any se-
quence of n bases in the genome to have exactly m mis-
matches, increases monotonically with m. This increase can
be expressed by the ratio of probabilities for sequences with
m versus m  1 mismatches, given by P(Dm)/P(Dm1) 
3((n  1)/m  1). The second factor R  k0n fm[P]/(1 
k0
n fm[P]), the fraction of PNA binding to such a sequence,
decreases monotonically with m. However, as long as con-
ditions are such that k0n fm[P]  1, R decreases very slowly
with m, and the terms grow with increasing m until k0n fm[P]
 1. We shall call this “breaking point” m value mbp. The
behavior of the terms after this point depends on the size of
the effective frustration factor f (likely to decrease as the
length of sequence or the number of mismatches increases).
If 1/f  3((n  1)/mbp  1), the subsequent terms in the
summation will rapidly decrease, and the concentration of
PNA bound to nontarget sequences can be approximated by
the maximum term in the summation with m  mbp. How-
ever, with a larger (less discriminating) frustration factor,
subsequent terms will decrease slowly, or even increase, in
case the total concentration of PNA bound has to include
also partially covered mismatched sequences with k0n fm[P]
 1 (nonspecific binding).
Therapeutic range
The total amount of PNA added to the solution (cell) will,
of course, always be the sum of free PNA and PNA bound
to the correct target and to all possible mismatched se-
quences. The species distributions will, however, depend
strongly on the binding situation, i.e., that part of the bind-
ing isotherm with which we are interested. Starting with the
expression for total PNA concentration according to Model
1 (Eq. 5), and using the frustration factor for an average
mismatch, f  k0/km, we have
[PNA]tot  P DNAtot k0nP1 k0nP Lm1
n
P	Dm
R .
(13)
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Consider now the free PNA concentration [P] in two lim-
iting situations. Case A, defined by the minimal free PNA
concentration [P] that will satisfactorily block the target,
i.e., when k0
n[P]  [PT]/[T]  , where , the ratio of
blocked to unblocked target, is introduced as an efficiency
parameter. Typically, we may want  to be on the order of
102–103. Because, by hypothesis, [P] is small enough that L
¥ P(Dm)R can be neglected, Eq. 13 then reduces to
[PNA]tot,A 

k0
n [DNA]tot. (14)
The other limit, case B, is the maximum [P] that can be
tolerated before the onset of binding to mismatched sequences
that have significant probabilities of occurring in the genome.
Let mcrit be the smallest value of m that gives P(Dm)L  0.1,
i.e., the minimal number of mismatches necessary for a se-
quence to occur with a significant (here 10%) probability. A
graph of n versusmcrit, shown in Fig. 6 for a genome of human
size, reveals an approximately linear relationship in which the
length n of the PNA has to be increased by between 2 and 3
bases to increase mcrit by one. For m  mcrit, we require that
k0
n fm[P]  [PDm]/[Dm]  , where  is the tolerance for
nontarget blockage (  0.1 means that 10% of a sequence
with mcrit mismatches will be blocked). Because only a small
fraction of the mismatched sequences Dm are blocked, the
expression within parenthesis in Eq. 13 is still close to unity
and thus leads to the approximation,
[PNA]tot,B 

k0
n f m
 DNAtot. (15)
To more easily assess what parameter to change to tune
the binding, we shall consider the “therapeutic ratio,” G,
defined by the limiting cases A and B,
G
highest safe [PNA]tot
lowest efficient [PNA]tot

[PNA]tot,B
PNA]tot,A

/m k0
nDNAtot
  k0
nDNAtot
. (16)
There are several implications of Eq. 16: 1) If mcrit  0,
no discrimination is possible, thus the minimal length n of
the PNA must be 19 bases (see Fig. 6). 2) The therapeutic
ratio G will be very close to unity unless / fm 
k0
n[DNA]tot, and / f
m . Because the DNA concentration
is not variable in this context, k0 may not be excessively
large. 3) If k0 is too large in comparison to the effective
frustration factor, leading to 1/f  k0
(2–3), an increase in the
length n of the PNA will, in fact, lead to a decrease in G. 4)
In contrast, because   k0
n[P], a too-small k0 will result in
the free PNA concentration [P] being too large, which
would be uneconomical and of potential danger with regard
to side effects from non-nucleic acid interactions.
A narrow therapeutic range has previously been observed
in vitro. Administration of PNA complementary to different
targets in mRNA was found to sequence-specifically inhibit
translation only within narrow limits (Bonham et al., 1995;
Gambacorti-Passerini et al., 1996). The usable range of
PNA concentrations is thus quite restrained if one wants to
achieve total binding to the target and, at the same time,
avoid extensive binding to nontarget sites, again stressing
the need for detailed understanding of the basic binding
properties of PNA and other sequence-specific DNA-bind-
ing agents.
Improving the model
The model we have presented here is quite simplistic from
several aspects. Again, it is easily expanded to include
additional determinants of the binding strength of PNA to
DNA, e.g., relative distribution of GC and AT basepairs
(GC%) and fractional pyrimidine content on the PNA strand
(Giesen et al., 1998). Expanding on such parametric factors,
one could incorporate influence of nearest-neighbor inter-
actions as has been determined for DNA–DNA hybridiza-
tion (Peyret et al., 1999). However, because the PNA–DNA
basepair is asymmetric, a much larger experimental data set
is required to extract nearest-neighbor parameters even for
matched basepairs, as pointed out previously (Giesen et al.,
1998).
For DNA–DNA hybridization, it has been shown that the
nearest neighbors in the sequence also influence mismatch
stability significantly, and the first complete study of ther-
modynamic nearest-neighbor parameters was reported by
Peyret et al. (1999). Stability of PNA–DNA basepairs is
FIGURE 6 Lengths of PNA sequences, n, corresponding to the critical
number of mismatches, mcrit, one has to consider while designing a specific
binding scenario for a genome with L  3  109 bases (see text). Line
represents linear fit n  15  2.6mcrit. The gamma function was used to
calculate mcrit from the condition P(Dmcrit1)  0.1 (see Eq. 5), to be able
to compute (m
n ) even for noninteger values of n and m.
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likewise expected to be highly context dependent, which
one should take into account when designing PNA oli-
gomers for targeting DNA or RNA sequences in both diag-
nostic and therapeutic applications and also when choosing
targets (Kilså Jensen et al., 1997; Ratilainen et al., 2000). A
first step to improving the model, besides a more sophisti-
cated categorization of mismatches, would be inclusion of
the composition of neighboring basepairs. We previously
found, for PNA–DNA duplexes with single mismatches
that, for example, flanking GC pairs, in general, seem to
stabilize the mismatch relative to flanking AT basepairs, a
behavior similar to what has been observed for DNA–DNA
(Peyret et al., 1999) and RNA–RNA duplexes (Zhu and
Wartell, 1997).
Relevance to gene targeting
As pointed out, the concrete output data of the simulations
should be treated with caution when applied to gene target-
ing. The results should mainly serve the purpose of identi-
fying critical features and how the present approach could
be applied once relevant thermodynamic data is available.
Thus, the results of our simulations particularly refer to
PNA, forming duplexes with single-stranded DNA. They
would thus apply, in principle, to antisense applications
once correction for the smaller mRNA genome and lower
concentration is made. The approach also directly applies to
minor-groove binding gene-targeting agents, such as those
invented by Dervan and co-workers (Herman et al., 1999).
However, for triplex-forming PNA gene-targeting strate-
gies, particular care has to be taken because of the kineti-
cally governed slow processes of strand invasion (Wittung
et al., 1996, 1997).
CONCLUSIONS
The statistical modeling of the hybridization properties of a
model ligand (PNA) to a model genome target (single-
stranded DNA) has been used to get insight into the basic
determinants of binding specificity. The main parameters in
this treatment have been the length of the PNA probe, the
average per-base binding constant k0, and the binding af-
finity loss, given by the frustration factor f  kmis/k0, of a
mismatched basepair. The specificity has been measured as
the range of safety of the total drug (PNA) concentration or
dose, defined as a therapeutic ratio G  maximum safe
[PNA]tot/minimal efficient [PNA]tot.
We find that, by far, the most important parameter with
respect to G is the average per-base binding constant k0, and
that only a rather narrow range of values gives rise to high
binding selectivity. Thus, the in vitro value determined
previously (Ratilainen et al., 2000) is too high to permit any
significant selectivity. For diagnostic purposes, the value of
k0 is readily modulated due to the substantial H associ-
ated with the equilibrium, and we find that a temperature of
55–60°C should be optimal for selective binding of PNA to
a single-stranded DNA of genomic proportions. For gene-
therapeutic purposes, however, the higher ionic strength in
the cell and the presence of other, competing DNA-binding
molecules (Boffa et al., 1996) including histone proteins in
chromatin will reduce the binding, which could be handled
by choosing a higher effective PNA concentration. Appro-
priate control of the binding constant of the gene-targeting
agent is thus required to optimize in vivo selectivity.
Our model is quite general, and, though simple, gives
insight about sequence-specific binding. Thus, it can be
applied to a variety of situations of molecules binding
sequence-specifically to a target, ranging from gene-target-
ing at various levels (antigene, antisense) to biotechnical
applications such as gene-sequencing and gene-diagnostics.
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